TickerGuard
Buy Day today: Neutral (51) Mixed market breadth · no major macro event
BIIB

Biogen Inc.

Healthcare · Drug Manufacturers - General

215.50$ -1.6% vs. previous close Closing price · As of: Sep 18, 2026

Statements

Cash Flow

All figures as a percentage of revenue in the same period.

Tick rows to compare them in a chart (up to 4)

Cash Flow BIIB
Line item 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
30.3% 34.5% 39.5% 37.1% 46.0% 49.2% 31.5% 33.1% 13.6% 15.7% 29.7% 22.5%
6.6% 5.6% 6.0% 8.8% 4.8% 3.2% 3.4% 4.4% 5.1% 5.0% 7.0% 7.9%
1.6% 1.5% 1.4% 1.0% 1.2% 1.3% 1.5% 2.2% 2.5% 2.7% 3.0% 3.0%
-2.1% 0.9% 0.6% 4.6% 2.2% 1.8% 5.0% 6.8% -14.5%
-5.0% -5.3% 0.6% 1.9% 3.0% 1.4% -1.4% -1.3% -8.8% -6.6% -1.6% -10.8%
3.0% 6.0% 5.4% 7.1% 5.7% 3.6% 4.1% 2.7% 2.4% 3.2% 3.7% 1.6%
-15.9% -42.3% -21.7% -24.1% -15.2% 3.3% -4.5% -5.1% 15.6% -41.6% -8.3% -14.0%
565.1% 55.1% 0.0% 2.5% 0.3% 0.0% 0.0%
-9.1% -46.5% -8.7% -11.1% -32.4% -40.8% -49.7% -16.4% -7.4% 0.0% 0.0%
0.0% 55.1% 0.0% -4.6% 0.0% 10.2% 10.9% -1.5% -9.9% 1.9% -6.7% -0.2%
-7.8% 9.2% -8.6% -19.4% -33.2% -40.8% -39.2% -19.0% -17.3% 1.4% -7.1% -3.1%
6.2% 1.0% 8.9% -6.1% -2.6% 11.7% -11.8% 8.5% 11.4% -24.1% 13.7% 6.5%
27.1% 28.6% 33.7% 30.0% 39.4% 45.7% 27.4% 30.5% 11.2% 12.6% 26.0% 20.9%

Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?